[
  {
    "ts": "2024-12-10T12:00:00+00:00",
    "headline": "BIO-TECHNE LAUNCHES ESR1 MUTATION MONITORING ASSAY",
    "summary": "Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, launched a highly sensitive ESR1 mutation monitoring assay. ESR1 gene mutations are known to be linked to hormone receptor-positive (HR+) metastatic breast cancer. The research-use-only assay, which consists of a qPCR detection kit as well as an isolation kit for cell-free DNA and exosomal RNA, will be featured in the Asuragen booth (#1429) at the San Antonio Breast Cancer Symposium beginning on December 10t",
    "url": "https://finance.yahoo.com/news/bio-techne-launches-esr1-mutation-120000864.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "ec3c2b63-8e06-3845-a80a-ae56e945aff6",
      "content": {
        "id": "ec3c2b63-8e06-3845-a80a-ae56e945aff6",
        "contentType": "STORY",
        "title": "BIO-TECHNE LAUNCHES ESR1 MUTATION MONITORING ASSAY",
        "description": "",
        "summary": "Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, launched a highly sensitive ESR1 mutation monitoring assay. ESR1 gene mutations are known to be linked to hormone receptor-positive (HR+) metastatic breast cancer. The research-use-only assay, which consists of a qPCR detection kit as well as an isolation kit for cell-free DNA and exosomal RNA, will be featured in the Asuragen booth (#1429) at the San Antonio Breast Cancer Symposium beginning on December 10t",
        "pubDate": "2024-12-10T12:00:00Z",
        "displayTime": "2024-12-10T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f5bd457eba951c97e17e98b5c3c3878c",
          "originalWidth": 400,
          "originalHeight": 146,
          "caption": "BT Logo (PRNewsfoto/Bio-Techne Corporation)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kJl8lfxgQq52fwY.Vvxfgw--~B/aD0xNDY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f5bd457eba951c97e17e98b5c3c3878c.cf.webp",
              "width": 400,
              "height": 146,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tkFsOYbYoGS0nXbE3BaqwA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f5bd457eba951c97e17e98b5c3c3878c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bio-techne-launches-esr1-mutation-120000864.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bio-techne-launches-esr1-mutation-120000864.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TECH"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]